...Finds No Link To Colon Cancer In Initial Trial, GSK And Boehringer Prevail In First Zantac Cancer Lawsuit...
Yahoo Finance · 13 hours ago
Open | 45.42 |
High | 45.45 |
Low | 45.03 |
Mkt Cap | 93.74B |
P/E (TTM) | 16.29 |
Div & Yield | 1.50 & 3.33% |
Prev. Close | 45.15 |
52 Wk. Low | 33.33 |
52 Wk. High | 45.93 |
Related stocks
(USD) | Q1 2024 | Y/Y |
---|---|---|
Revenue | 7.36B | 5.90% ▲ |
Net Income | 1.05B | 29.80% ▼ |
Diluted EPS | 1.09 | 30.40% ▼ |
Quarter | EPS Estimate | EPS Actual |
---|---|---|
Q2 2024 | $0.98 | - |
Q1 2024 | $0.91 | $1.09 |
Q4 2023 | $0.76 | $0.72 |
S&P 500^GSPC | 5,304.72+36.88 (+0.70%) |
Dow 30^DJI | 39,069.59+4.33 (+0.01%) |
Nasdaq^IXIC | 16,920.79+184.76 (+1.10%) |
19.00+3.71% | |
0.9830+428.49% | |
809.73+1.68% |